Targeting Phosphatidylserine in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas: A Phase 2 Trial of Bavituximab Plus Pembrolizumab with Biomarker-Correlated Outcomes.

Keytruda (pembrolizumab) - Merck (MSD)

Tarvacin (bavituximab) - Feng Biosciences

http://www.ncbi.nlm.nih.gov/pubmed/42346219

Colleen Mockbee; Haeseong Park; Hagop Youssoufian; Ian Chau; Jeeyun Lee; Kerry Culm; Laura Benjamin; Mark Uhlik; Panagiotis Ntellas

Jun 26, 2026